Zoonotic illnesses such as monkeypox and Ebola are potential bioweapons, and the Defense Threat Reduction Agency is funding research into how two cancer medications -- Gleevec and Tasigna -- could serve as a defense against such attacks. The idea is that the drugs could slow an infection, allowing the immune system to mount an effective response. Scientists hope to develop a general defense against a variety of potential bioweapons because producing a separate drug for use against each agent is not practical.

Full Story:

Related Summaries